|
|
| | GW694590A Basic information |
| Product Name: | GW694590A | | Synonyms: | GW694590A;Carbamic acid, N-[6-[4-[[(phenylamino)carbonyl]amino]phenoxy]-1H-benzimidazol-2-yl]-, methyl ester | | CAS: | 948313-24-4 | | MF: | C22H19N5O4 | | MW: | 417.42 | | EINECS: | | | Product Categories: | | | Mol File: | 948313-24-4.mol |  |
| | GW694590A Chemical Properties |
| density | 1.462±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 11.961±0.10(predicted) |
| | GW694590A Usage And Synthesis |
| Uses | GW694590A (UNC10112731) is a MYC protein stabilizer that increases endogenous MYC protein levels. GW694590A also targets receptor tyrosine kinases, inhibiting DDR2, KIT and PDGFRα by 81% at 1 μM. , 68% and 67%. GW694590A is a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential effects on the Fluc reporter gene[1]. | | References | [1] Blake DR, et al. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Sci Signal. 2019 Jul 16;12(590):eaav7259. DOI:10.1126/scisignal.aav7259
[2] Dranchak P, et al. Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays. PLoS One. 2013;8(3):e57888. DOI:10.1371/journal.pone.0057888 |
| | GW694590A Preparation Products And Raw materials |
|